Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84931 trials found · Page 40 of 4247
-
Double-Punch cell therapy trial launches for patients out of options
Disease control Not yet recruitingThis study is a single-arm, open-label, prospective clinical trial, with patients suffering from refractory and relapsed acute myeloid leukemia as the subjects. It plans to enroll 10 cases to evaluate the safety and efficacy of sequential CD123+CLL-1 CAR-T cells followed by CD7 C…
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
Robot surgeons guided by AI target deadly brain bleeds
Disease control Recruiting nowA nationwide, prospective, multicenter randomized controlled clinical trial to evaluate the therapeutic effects of the fiber tract-based artificial intelligence (AI) Robot Guiding System on the perioperative and long-term recovery of patients with moderate-volume basal ganglion h…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
New hope for tough bladder cancers: trial tests novel drug combo
Disease control Recruiting nowA Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
New targeted therapy enters final testing for Tough-to-Treat lung cancer
Disease control Recruiting nowThis trial is a registrational phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with first-line treatment of HER2-mutant advanced or metastatic non-squamous non-small cell lung cancer.
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
Major trial tests new weapon against Tough-to-Treat lung cancer
Disease control Recruiting nowThe purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment w…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
New cell therapy aims to control blood cancer and protect kidneys
Disease control Recruiting nowThe purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal dysfunction.
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
New hope for prostate cancer patients: major trial tests powerful drug duo
Disease control Recruiting nowThis study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Diabetes drug could be key to slowing dementia
Disease control Recruiting nowThe LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 420 type 2 diabetes patients with early dementia are randomized 1:1 to either the active treatment group (receiving subcutaneous injections of ma…
Phase: PHASE3 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
Major trial aims to boost survival for untreated leukemia patients
Disease control Recruiting nowZiftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that wi…
Phase: PHASE3 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New Two-Pronged attack on deadly blood cancers in seniors
Disease control Recruiting nowThis phase II trial tests the safety, side effects, and how well combination chemotherapy with fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin (FLAG-Ida) followed immediately by reduced-intensity total body radiation therapy, calle…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New CAR-T therapy targets Hard-to-Treat brain cancer in early trial
Disease control Recruiting nowThis study is an investigator-initiated, open-label Phase I clinical trial designed to evaluate the safety and efficacy of EPC-003 fully human anti-B7H3/IL13Ra2 armored Chimeric Antigen Receptor T-Cell Therapy (CAR-T) cell injection in patients with recurrent or refractory gliobl…
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New hope for tough childhood cancers: Three-Drug combo enters testing
Disease control Recruiting nowTo learn if giving the study drugs calaspargase pegol-mknl and decitabine in combination with venetoclax can help to control relapsed/refractory T-ALL and T-LLy. The safety of this drug combination will also be studied.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
Cancer trial aims to ditch harsh chemo for gentler immunotherapy
Disease control Not yet recruitingThis phase III trial aims to evaluate the efficacy and safety of induction chemotherapy combined with serplulimab (induction/maintenance therapy) with omission of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC).
Phase: PHASE3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Experimental CAR-T therapy aims to fight back against tough blood cancers
Disease control Recruiting now\*\*Translation:\*\* This clinical trial is designed as a single-arm, open-label, multicenter study. After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells. Following lymphodepletion pretreatm…
Phase: PHASE2 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug duo aims to wipe out breast cancer before surgery
Disease control Recruiting nowThe purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Phase: PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
New hope for tough stomach cancers: major trial tests promising drug
Disease control Recruiting nowThis trial is a registrational Phase III, randomized, controlled, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-positive locally advanced or metastatic gastric or gastro-esophageal junction (G/GEJ) adenocarcinoma afte…
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
New contender takes on blockbuster wegovy in Head-to-Head weight loss showdown
Disease control Recruiting nowThis study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate the efficacy and safety of GZR18 Injection in this…
Phase: PHASE3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Apr 13, 2026 20:09 UTC
-
New hope for Tough-to-Treat lung cancer: phase 3 trial tests Next-Generation pill
Disease control Not yet recruitingThe primary purpose of the study was to compare progression-free survival of JYP0322 vs. platinum-based doublet chemotherapy in patients previously treated with ROS1-TKIs. Patients in the chemotherapy arm are given the option to switch to JYP0322 after BICR confirmed progressive …
Phase: PHASE3 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated Apr 07, 2026 14:35 UTC
-
Brain cell transplant trial offers new hope for Parkinson's patients
Disease control Recruiting nowThis study is a Phase I/II clinical study to evaluate the safety, tolerability, and efficacy of XS411 in the treatment of EOPD. The study consists of two phases: Phase I and Phase II. Phase I study is planned to be conducted in patients with EOPD, using a single-arm, open-label,…
Phase: PHASE1, PHASE2 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
New hope for kids with aggressive cancer: scientists re-engineer immune cells to fight tumors
Disease control Recruiting nowBackground: Rhabdomyosarcoma (RMS) is a cancer of soft tissues. It is the most common soft tissue sarcoma seen in children. RMS cancer cells have a protein called FGFR4 on their surface. Researchers want to try a new kind of treatment for RMS: They will collect a person s own T …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 07, 2026 14:37 UTC